Cantargia AB (publ) (CANTA) Preclinical Data Back Nadunolimab+RASi, Phase 1b/2a Planned

Cantargia reported preclinical data from Fred Hutch showing nadunolimab plus a RAS inhibitor reduced tumor burden and immune suppression in PDAC models, supporting a planned Phase 1b/2a trial.Material DetailsContext by AI AnalystThis is early-stage, preclinical support aligning with Cantargia’s pus…